Can you take Chloramphenicol / hydrocortisone / polymyxin b ophthalmic with Ziftomenib?

The chloramphenicol ophthalmic in chloramphenicol / hydrocortisone / polymyxin b ophthalmic has a major potential interaction with Bone Marrow Depression/Low Blood Counts.

Chloramphenicol may cause bone marrow depression and other hematologic toxicities, which can be irreversible or reversible. The former type is independent of dose and results in aplastic anemia with a high rate of mortality, generally from hemorrhage or infection. It has been reported following both systemic and topical administration of chloramphenicol and has an estimated incidence of 1 in 25,000 to 1 in 40,000 courses of therapy. Bone marrow aplasia or hypoplasia may occur after a single dose but more often develops weeks or months after the drug has been discontinued. A reversible myelosuppression occurs much more frequently and is characterized by anemia, vacuolation of red blood cells, decreased reticulocyte count, leukopenia, thrombocytopenia, increased serum iron concentrations, and increased serum iron-binding capacity. It is dose-dependent, occurring regularly at chloramphenicol dosages exceeding 4 g/day (in adults) or at plasma drug concentrations >= 25 mcg/mL, and usually responds to withdrawal of the drug. Therapy with chloramphenicol should be administered cautiously, if at all, in patients with preexisting blood dyscrasias and/or bone marrow depression. Complete blood counts and differential reticulocyte counts should be performed in all patients prior to initiating therapy and approximately every 2 days during therapy. Marked depression of blood counts and/or development of other hematologic abnormalities may be indication for withdrawal of chloramphenicol therapy.

The hydrocortisone ophthalmic in chloramphenicol / hydrocortisone / polymyxin b ophthalmic has a major potential interaction with Cataract.

Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves. Therapy with ophthalmic corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure. If these agents are used for more than 10 days, the manufacturers recommend that intraocular pressure be routinely monitored, including in children. The equatorial and posterior subcapsular portions of the lens should be examined for changes.

Ziftomenib has a moderate potential interaction with Electrolyte Abnormalities.

Ziftomenib can cause QT (QTc) interval prolongation. Patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or who are taking medications known to prolong the QTc interval may require more frequent ECG monitoring. Perform an ECG and correct electrolyte abnormalities prior to starting treatment; do not initiate if QTcF is greater than 480 msec. Monitor ECG at least once weekly for the first 4 weeks of therapy, and at least monthly thereafter.

The hydrocortisone ophthalmic in chloramphenicol / hydrocortisone / polymyxin b ophthalmic has a major potential interaction with Eye Conditions.

The use of ophthalmic corticosteroids is contraindicated in most viral diseases of the cornea and conjunctiva, including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella; fungal diseases of ocular structures; mycobacterial infections, including tuberculosis, of the eye; and any acute, purulent, untreated ocular infections. Corticosteroids may decrease host resistance to infectious agents, thus prolonging the course and/or exacerbating the severity of the infection while encouraging the development of new or secondary infection. In addition, administration of ophthalmic corticosteroids in severe ocular disease, especially acute herpes simplex keratitis, may lead to excessive corneal and scleral thinning, increasing the risk for perforation. In less serious ocular infections, therapy with ophthalmic corticosteroids may be administered but only with caution and accompanied by appropriate antimicrobial agents. Besides compromising host immune response, corticosteroids may also mask the symptoms of infection, thus hindering the recognition of potential ineffectiveness of the antibiotic therapy. If infection does not improve or becomes worse during administration of an ophthalmic corticosteroid, the drug should be discontinued and other appropriate therapy initiated.

The hydrocortisone ophthalmic in chloramphenicol / hydrocortisone / polymyxin b ophthalmic has a major potential interaction with Glaucoma/Intraocular Hypertension.

Prolonged use of corticosteroids may cause posterior subcapsular cataracts and elevated intraocular pressure, the latter of which may lead to glaucoma and/or damage to the optic nerves. Therapy with ophthalmic corticosteroids should be administered cautiously in patients with a history of cataracts, glaucoma, or increased intraocular pressure. If these agents are used for more than 10 days, the manufacturers recommend that intraocular pressure be routinely monitored, including in children. The equatorial and posterior subcapsular portions of the lens should be examined for changes.

Ziftomenib has a moderate potential interaction with Heart Failure.

Ziftomenib can cause QT (QTc) interval prolongation. Patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or who are taking medications known to prolong the QTc interval may require more frequent ECG monitoring. Perform an ECG and correct electrolyte abnormalities prior to starting treatment; do not initiate if QTcF is greater than 480 msec. Monitor ECG at least once weekly for the first 4 weeks of therapy, and at least monthly thereafter.

Ziftomenib has a moderate potential interaction with Liver Disease.

The pharmacokinetics of ziftomenib have not been studied in patients with severe liver dysfunction. No adjustment recommended in patients with mild to moderate liver dysfunction.

Ziftomenib has a moderate potential interaction with Long QT Syndrome.

Ziftomenib can cause QT (QTc) interval prolongation. Patients with congenital long QTc syndrome, congestive heart failure, electrolyte abnormalities, or who are taking medications known to prolong the QTc interval may require more frequent ECG monitoring. Perform an ECG and correct electrolyte abnormalities prior to starting treatment; do not initiate if QTcF is greater than 480 msec. Monitor ECG at least once weekly for the first 4 weeks of therapy, and at least monthly thereafter.

Ziftomenib has a moderate potential interaction with Renal Dysfunction.

The pharmacokinetics of ziftomenib have not been studied in patients with severe renal dysfunction. No adjustment recommended in patients with mild to moderate renal dysfunction.